2.0264
price down icon7.66%   -0.1936
 
loading
Schlusskurs vom Vortag:
$2.22
Offen:
$2.23
24-Stunden-Volumen:
1.44M
Relative Volume:
0.90
Marktkapitalisierung:
$239.75M
Einnahmen:
$13.45M
Nettoeinkommen (Verlust:
$-178.23M
KGV:
-0.9338
EPS:
-2.17
Netto-Cashflow:
$-132.53M
1W Leistung:
-1.44%
1M Leistung:
-34.92%
6M Leistung:
-44.59%
1J Leistung:
-16.33%
1-Tages-Spanne:
Value
$2.01
$2.2799
1-Wochen-Bereich:
Value
$1.96
$3.50
52-Wochen-Spanne:
Value
$1.96
$8.83

Fate Therapeutics Inc Stock (FATE) Company Profile

Name
Firmenname
Fate Therapeutics Inc
Name
Telefon
858.875.1803
Name
Adresse
12278 SCRIPPS SUMMIT DRIVE, SAN DIEGO, CA
Name
Mitarbeiter
181
Name
Twitter
@fatethx
Name
Nächster Verdiensttermin
2024-11-06
Name
Neueste SEC-Einreichungen
Name
FATE's Discussions on Twitter

Vergleichen Sie FATE mit anderen Aktien

Aktien Preis Marktkapitalisierung Umsatz Nettogewinn Free Cashflow ENV
FATE 2.05 239.75M 13.45M -178.23M -132.53M -2.17
VRTX 449.14 115.43B 10.63B -479.80M -1.35B 13.33
REGN 748.83 82.04B 13.85B 4.65B 3.32B 35.06
ARGX 587.39 35.30B 1.86B -40.29M -1.28B -4.16
ALNY 248.01 32.04B 2.09B -332.26M 16.06M -4.14
BNTX 106.99 24.89B 3.30B -501.07M 1.03B 11.54

Fate Therapeutics Inc Stock (FATE) Upgrades & Downgrades

Datum Aktion Analytiker Ratingänderung
2024-06-17 Hochstufung Piper Sandler Neutral → Overweight
2023-03-27 Fortgesetzt Wells Fargo Equal Weight
2023-01-24 Herabstufung H.C. Wainwright Buy → Neutral
2023-01-06 Herabstufung BMO Capital Markets Outperform → Market Perform
2023-01-06 Herabstufung BofA Securities Buy → Underperform
2023-01-06 Herabstufung Cowen Outperform → Market Perform
2023-01-06 Herabstufung Piper Sandler Overweight → Neutral
2023-01-06 Herabstufung Stifel Buy → Hold
2023-01-06 Herabstufung Truist Buy → Hold
2023-01-06 Herabstufung Wedbush Outperform → Neutral
2023-01-03 Herabstufung Guggenheim Buy → Neutral
2022-12-22 Herabstufung Oppenheimer Outperform → Perform
2022-12-15 Eingeleitet Goldman Sell
2022-11-04 Fortgesetzt Cantor Fitzgerald Overweight
2022-10-10 Eingeleitet Canaccord Genuity Buy
2022-08-18 Fortgesetzt Wells Fargo Overweight
2022-07-28 Eingeleitet Needham Hold
2022-07-11 Hochstufung BMO Capital Markets Market Perform → Outperform
2022-06-03 Eingeleitet Robert W. Baird Neutral
2022-02-11 Fortgesetzt BMO Capital Markets Market Perform
2021-12-15 Hochstufung Wedbush Neutral → Outperform
2021-12-07 Eingeleitet Cowen Outperform
2021-11-09 Hochstufung Citigroup Neutral → Buy
2021-08-26 Eingeleitet Morgan Stanley Equal-Weight
2021-06-07 Hochstufung H.C. Wainwright Neutral → Buy
2021-05-07 Hochstufung Wedbush Neutral → Outperform
2021-04-26 Fortgesetzt Jefferies Buy
2021-02-26 Eingeleitet BofA Securities Buy
2021-02-26 Herabstufung Wedbush Outperform → Neutral
2021-02-11 Herabstufung Citigroup Buy → Neutral
2021-01-27 Fortgesetzt H.C. Wainwright Neutral
2020-05-13 Eingeleitet H.C. Wainwright Buy
2020-03-04 Eingeleitet Barclays Overweight
2020-01-09 Herabstufung BMO Capital Markets Outperform → Market Perform
2019-12-30 Bestätigt Mizuho Buy
2019-12-09 Hochstufung Wells Fargo Market Perform → Outperform
2019-11-12 Eingeleitet SunTrust Buy
2019-11-06 Herabstufung Wells Fargo Outperform → Market Perform
2019-10-01 Eingeleitet Stifel Buy
2019-08-09 Eingeleitet BTIG Research Buy
2019-07-22 Eingeleitet Cantor Fitzgerald Overweight
2019-07-12 Eingeleitet Oppenheimer Outperform
2019-06-13 Eingeleitet Mizuho Buy
2019-06-07 Eingeleitet ROTH Capital Neutral
2019-05-31 Eingeleitet Guggenheim Buy
2019-05-24 Fortgesetzt Citigroup Buy
2019-03-28 Eingeleitet SVB Leerink Outperform
2019-01-03 Herabstufung Stephens Overweight → Equal-Weight
2018-11-05 Eingeleitet Jefferies Buy
2018-08-01 Eingeleitet Citigroup Buy
2018-03-06 Herabstufung H.C. Wainwright Buy → Neutral
Alle ansehen

Fate Therapeutics Inc Aktie (FATE) Neueste Nachrichten

pulisher
Nov 20, 2024

FATE Presents Encourgaing Data From Lupus Study, Stock Gains - MSN

Nov 20, 2024
pulisher
Nov 20, 2024

Fate Therapeutics: FT819 Finding Bodes Well For Future Of SLE Treatment Options - Seeking Alpha

Nov 20, 2024
pulisher
Nov 20, 2024

Fate stock closes 12% higher after soaring 73% on drug data (update) - MSN

Nov 20, 2024
pulisher
Nov 19, 2024

Needham & Company LLC Reaffirms Hold Rating for Fate Therapeutics (NASDAQ:FATE) - MarketBeat

Nov 19, 2024
pulisher
Nov 19, 2024

Fate Thera rockets on early data for FT819 - The Pharma Letter

Nov 19, 2024
pulisher
Nov 18, 2024

Analyst cites quality-of-life improvements while maintaining Hold on Fate Therapeutics stock - Investing.com

Nov 18, 2024
pulisher
Nov 18, 2024

BofA upgrades Fate Therapeutics to neutral; target to $3 from $3.50 By Investing.com - Investing.com UK

Nov 18, 2024
pulisher
Nov 18, 2024

Stock market today: Fate Therapeutics gains 70.79% whereas SiNtx Technologies rose by 38.73% in early trading - Business Upturn

Nov 18, 2024
pulisher
Nov 18, 2024

Fate Therapeutics Presents 6-Month Follow-up Data on First - GlobeNewswire

Nov 18, 2024
pulisher
Nov 18, 2024

Fate Therapeutics (FATE) Presents 6-Month Follow-up Data on First Patient Treated in Phase 1 Autoimmunity Study - StreetInsider.com

Nov 18, 2024
pulisher
Nov 18, 2024

Fate Therapeutics Highlights FT522 Off-the-shelf, ADR-armed - GlobeNewswire

Nov 18, 2024
pulisher
Nov 18, 2024

Fate Therapeutics Highlights FT522 Off-the-shelf, ADR-armed CAR NK Cell Product Candidate at 2024 ACR Convergence - Yahoo Finance

Nov 18, 2024
pulisher
Nov 15, 2024

Wedbush Decreases Earnings Estimates for Fate Therapeutics - MarketBeat

Nov 15, 2024
pulisher
Nov 15, 2024

Fate Therapeutics, Inc. (NASDAQ:FATE) Reported Earnings Last Week And Analysts Are Already Upgrading Their Estimates - Yahoo Finance

Nov 15, 2024
pulisher
Nov 14, 2024

Fate Therapeutics Third Quarter 2024 Earnings: Beats Expectations - Yahoo Finance

Nov 14, 2024
pulisher
Nov 14, 2024

Fate Therapeutics’ Stock Volatility: Impact of Partnerships and Regulatory Challenges - TipRanks

Nov 14, 2024
pulisher
Nov 13, 2024

Fate Therapeutics Unveils Q3 2024 Financial Highlights - TipRanks

Nov 13, 2024
pulisher
Nov 13, 2024

FATE Q3 Earnings Beat on Higher Revenues, Pipeline in Focus - Yahoo Finance

Nov 13, 2024
pulisher
Nov 13, 2024

BMO cuts Fate Therapeutics stock target, keeps market rating on initial data - Investing.com UK

Nov 13, 2024
pulisher
Nov 13, 2024

Fate Therapeutics (NASDAQ:FATE) Given Hold Rating at Needham & Company LLC - MarketBeat

Nov 13, 2024
pulisher
Nov 13, 2024

Fate Therapeutics: Q3 Earnings Snapshot - CT Insider

Nov 13, 2024
pulisher
Nov 12, 2024

Fate Therapeutics earnings beat by $0.02, revenue topped estimates - Investing.com UK

Nov 12, 2024
pulisher
Nov 12, 2024

Fate Therapeutics (FATE) Reports Q3 Loss, Tops Revenue Estimates - Yahoo Finance

Nov 12, 2024
pulisher
Nov 12, 2024

Fate Therapeutics Reports Third Quarter 2024 Financial Results and Business Updates - The Manila Times

Nov 12, 2024
pulisher
Nov 09, 2024

Fate Therapeutics Highlights Cancer-selective, HER2-Targeting Profile of FT825 / ONO-8250 CAR T-cell Product Candidate for Treatment of Advanced Solid Tumors at 2024 SITC Annual Meeting - The Manila Times

Nov 09, 2024
pulisher
Nov 09, 2024

Fate Therapeutics Highlights Cancer-selective, - GlobeNewswire

Nov 09, 2024
pulisher
Nov 09, 2024

Fate Therapeutics Highlights Cancer-selective, HER2-Targeting Profile of FT825 / ONO-8250 CAR T-cell Product Candidate for Treatment of Advanced Solid Tumors at 2024 SITC Annual Meeting - GlobeNewswire Inc.

Nov 09, 2024
pulisher
Nov 08, 2024

Fate Therapeutics Presents Pan-tumor Targeting Preclinical - GlobeNewswire

Nov 08, 2024
pulisher
Nov 08, 2024

Fate Therapeutics (NASDAQ:FATE) Stock Crosses Below 200 Day Moving AverageHere's Why - MarketBeat

Nov 08, 2024
pulisher
Nov 08, 2024

Fate Therapeutics, Inc. (NASDAQ:FATE) Given Consensus Rating of "Hold" by Brokerages - MarketBeat

Nov 08, 2024
pulisher
Nov 07, 2024

Fate Therapeutics Inc (FATE) Worth Considering For The Next Few Weeks - Stocks Register

Nov 07, 2024
pulisher
Nov 07, 2024

Karyopharm Therapeutics Inc (KPTI) Is Worth Accumulating At Current Levels - Stocks Register

Nov 07, 2024
pulisher
Nov 04, 2024

Global T-cell Therapy Market Trend [2024-2032] | Consumer Demographics - WICZ

Nov 04, 2024
pulisher
Nov 04, 2024

Fate Therapeutics Reports New Employee Inducement Award Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times

Nov 04, 2024
pulisher
Oct 25, 2024

Fate Therapeutics Drops To US$2.81, Yet Insiders May Have Sold Too Early - Simply Wall St

Oct 25, 2024
pulisher
Oct 22, 2024

ROSEN, TRUSTED INVESTOR COUNSEL, Encourages Fate Therapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class ActionFATE - AsiaOne

Oct 22, 2024
pulisher
Oct 17, 2024

Kymera Therapeutics, Inc. (NASDAQ:KYMR) Sees Significant Decrease in Short Interest - Defense World

Oct 17, 2024
pulisher
Oct 16, 2024

Fate Therapeutics, Inc. (NASDAQ:FATE) Short Interest Down 5.7% in September - MarketBeat

Oct 16, 2024
pulisher
Oct 16, 2024

Fate Therapeutics Inc (FATE) looking to reclaim success with recent performance - SETE News

Oct 16, 2024
pulisher
Oct 15, 2024

Was Fate Therapeutics Inc (FATE)’s session last reading good? - US Post News

Oct 15, 2024
pulisher
Oct 14, 2024

Market Recap Check: Fate Therapeutics Inc (FATE)’s Positive Finish at 3.09, Up/Down 5.10 - The Dwinnex

Oct 14, 2024
pulisher
Oct 14, 2024

Fate Therapeutics, Inc. (NASDAQ:FATE) Receives Average Rating of "Hold" from Analysts - MarketBeat

Oct 14, 2024
pulisher
Oct 09, 2024

Fate Therapeutics Inc [FATE] stock was sold by Xu Yuan at the price of US$2678.0 - Knox Daily

Oct 09, 2024
pulisher
Oct 09, 2024

Dimensional Fund Advisors LP Has $6.99 Million Holdings in Fate Therapeutics, Inc. (NASDAQ:FATE) - MarketBeat

Oct 09, 2024
pulisher
Oct 08, 2024

Holdings of Fate Therapeutics Inc (FATE) are aligned with the stars - SETE News

Oct 08, 2024
pulisher
Oct 08, 2024

Fate Therapeutics Inc (FATE) Stock: Heads Or Tails? - Stocks Register

Oct 08, 2024
pulisher
Oct 07, 2024

The Fate Therapeutics Inc (FATE) Stock Is Headed for a Correction - US Post News

Oct 07, 2024
pulisher
Oct 07, 2024

Market Insight: Fate Therapeutics Inc (FATE)’s Notable Gain, Closing at 3.22 - The Dwinnex

Oct 07, 2024
pulisher
Oct 04, 2024

Renaissance Technologies LLC Takes Position in Fate Therapeutics, Inc. (NASDAQ:FATE) - MarketBeat

Oct 04, 2024
pulisher
Oct 03, 2024

Fate Therapeutics Inc: A Year of Highs, Lows, and Market Resilience - The InvestChronicle

Oct 03, 2024

Finanzdaten der Fate Therapeutics Inc-Aktie (FATE)

Umsatz

loading

Nettogewinn

loading

Free Cashflow

loading

ENV

loading
$18.98
price up icon 1.80%
$70.68
price down icon 0.42%
$38.38
price up icon 3.49%
$369.83
price up icon 1.48%
$196.58
price up icon 0.88%
$102.64
price up icon 0.27%
Kapitalisierung:     |  Volumen (24h):